Published in Vaccine Weekly, January 7th, 2004
Under current license agreements, GSK incorporates Corixa's MPL adjuvant in several of its vaccines in development, including Cervarix vaccine for the prevention of human papillomavirus (HPV) infection and Simplirix vaccine for the prevention of genital herpes. In a presentation to its investors in London on December 3, 2003, GSK highlighted a variety of programs, including Cervarix and Simplirix containing Corixa's MPL adjuvant, as promising and novel treatments with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.